In this single-centre retrospective study, we analysed risk factors for nonrelapse long-term morbidity and mortality in patients with acute myeloblastic leukaemia (AML) who had undergone allogeneic transplantation. A total of 112 patients with de novo AML in first complete remission (CR1), n ¼ 90 or second complete remission (CR2, n ¼ 22) who received un-manipulated bone marrow grafts from human leukocyte antigen identical siblings between January 1985 and August 2000 were included. Of these, 97 patients alive and disease-free for at least 100 days after transplant were selected for the purpose of this longterm analysis. The use of an intensified conditioning regimen, Gram-negative bacteriaemia before transplantation, year of transplantation and number of pretransplant chemotherapy courses for patients in CR1 significantly affected the 7-year event-free survival which was 57%. 7-year transplant-related mortality TRM was 22%. Significant predictors for TRM were: bacterial infections before transplantation, major ABO blood group incompatibility, late severe bacterial infections, and chronic (graft-versus-host disease) GvHD. Predictive factors for late severe bacterial infections were infections before transplant, total body irradiation and GvHD. Incidence and risk factors for other late events including, chronic GvHD, late infections, osteonecrosis, cataract, endocrinecardiac-and lung-complications, cancer and performance status at last follow-up were also studied. The analysis strongly suggests that the combination of pretransplant factors such as chemotherapy and conditioning, and post transplant factors such as chronic GvHD had a major impact on late nonrelapse morbidity and mortality.
It has been shown in multicentre randomised trials that allogeneic stem cell transplantation (SCT) is the most effective strategy for preventing relapse in patients in first complete remission (CR) of acute myeloblastic leukaemia (AML). [1] [2] [3] [4] [5] [6] However, in adult patients, this benefit does not necessarily lead to a better disease-free survival, since allogeneic SCT is associated with significant transplantrelated mortality (TRM). 2, 7 In adults with good-risk AML, because chemotherapy alone or combined with differentiating agents can lead to sustained CR and cures, allogeneic SCT is usually indicated in second CR or first untreated relapse. 8, 9 In poor-risk AML, salvage rates are less predictable and the probability of reaching a second CR less certain; thus, allogeneic SCT is usually considered earlier, in first CR. [10] [11] [12] Finally, age is also a determinant in the indication for allogeneic SCT. 3, 13 Constant improvements in the management of transplanted patients have resulted in increasing number of long-term survivors following allogeneic SCT. 14, 15 However, the mortality rate of these long-term survivors is still higher than that of an age-matched population. [16] [17] [18] [19] Information on late outcomes and identification of risk factors should help to improve treatment strategies aimed at reducing late transplant-induced morbidity. We assessed the long-term outcome of 97 patients who underwent allogeneic SCT for AML in first or second CR at Saint Louis Hospital.
Patients and methods

Patient characteristics
A total of 112 patients with de novo AML in first (n ¼ 90) or second CR (n ¼ 22) were transplanted, using unmanipulated bone marrow grafts from human leukocyte antigen (HLA) identical siblings from January 1985 to August 2000 at Saint Louis hospital. The median follow-up from the date of transplantation was 5.5 years (range: 7 months to 13.2 years), 24 patients being alive for at least 7 years from transplantation. Patient and disease characteristics are listed in Table 1 . The 7-year TRM, event-free survival (EFS) and overall survival (OS) were 29, 47 and 55%, respectively. From this group, 97 patients alive and disease-free for at least 100 days after transplant were selected for the purpose of this long-term analysis. The 15 deaths before day À100 post-transplantation were mainly transplant-related [acute graft-versus-host disease (GvHD) (n ¼ 8), haemorrhage (n ¼ 2), infection without GvHD (n ¼ 2), rejection (n ¼ 1)], while two patients died from early relapse. Cytogenetics were available in 67.9% of recipients. Patients were classified into three cytogenetics groups as good risk [t(15;17) , inv (16) All patients had received a 'cytarabine-anthracycline' based induction regimen according to the ongoing protocols in use during the different time periods. 13, [20] [21] [22] Those less than 20 years old were more likely to be transplanted in first CR than the others (92 vs 75%, P ¼ 0.03). Patients transplanted in first CR received intermediate or high-dose cytarabine (HiDAC) less frequently (16% in the CR1 group vs 67% in the CR2 group, Po0.001). Chemotherapy regimens were not more intensive for the group of patients who had received more than three postremission chemotherapy courses (CTs): 24% HiDAC and 52% ambulatory amsacrine plus cytarabine vs 19 and 40% for the others.
Transplantation procedure
Transplant characteristics of the 97 patients who survived beyond day 100 are summarised in Table 2 . In all, 79 patients received standard conditioning regimens (81%), that is, cyclophosphamide (Cy) 120 mg/kg plus TBI 12 Gy (n ¼ 34) or busulfan (Bu) 16 mg/kg plus Cy 120 or 150 mg/ kg (n ¼ 46). The remaining patients (n ¼ 17) received either Bu/Cy or Cy/TBI plus one of the following drugs: etoposide, melphalan, high-dose aracytine, or BCNU. These intensified conditioning regimens were more frequently used for patients in CR2 (8% in CR1 vs 61% in CR2, Po0.001). Nucleated cell dose infused per kilogram recipient body weight was lower when there was a major ABO blood group incompatibility (median: 1.1 Â 10 8 /kg with a major ABO incompatibility vs 3.5 Â 10 8 /kg without major incompatibility, Po0.001). Most patients received cyclosporine (CsA) and methotrexate (MTX) as GvHD prophylaxis. 23, 24 All patients were treated in laminar air flow rooms and received oral amoxicilline, ofloxacine, fluconazole, amphotericin B and acyclovir as prophylaxis. Fluconazole was stopped when patients had an absolute neutrophil count (ANC) above 1 Â 10 9 /l and were off corticosteroids. Amoxicilline was continued for at least 5 years post transplantation. Prophylaxis against Pneumocystis carinii and Toxoplasmosis was started after neutrophil recovery and continued for at least 6 months or until corticosteroids had been stopped.
Definitions
End points were assessed on the date of last patient contact and analysed as of September 2001. Acute and chronic GvHD were graded according to the Seattle criteria. 25, 26 Analysis of chronic GvHD included patients who were alive with engraftment at day 100 post transplantation, cases being coded as absent, limited or extensive. Relapse was diagnosed according to cytological criteria. Deaths not attributable to disease -during continuous CR -were considered as events for the assessment of TRM. Second transplants for graft failure or rejection, relapse and death were considered as events to estimate EFS. OS was measured from the time of transplantation to the time of death. Patients not in CR at the time of death were considered to have died of relapse, even if this was not recorded as the immediate cause of death. Similarly, patients in CR with GvHD at the time of death were considered to have died of GvHD even if it was not the immediate cause of death. When analysing infectious complications arising after day 100, bacteriaemia, septic shock, pneumonia, intra-abdominal sepsis, acute pyelonephritis, meningitis, osteitis, arthritis, and empyema were considered as late severe bacterial infections (LSBI). Cytomegalovirus (CMV) infection and disease were defined according to standard criteria. 27, 28 Patients who relapsed or received a second transplant were censored at the time of relapse or second transplant when analysing incidence and predictors for late infections. 
Statistical methods
Chronic GvHD, late infections, TRM, cataracts, aseptic osteonecrosis, relapse incidence, EFS and OS incidence were estimated from the date of transplant. Analyses focused on projected probability of 7-year outcome. Groups were compared using the two-tailed log-rank test. In order to dichotomise continuous covariates, P-spline method and a penalised Cox model were used. The following covariates were analysed on univariate analysis: cytological subtype at diagnosis, cytogenetics, type of anthracycline regimen used during induction, dose of cytarabine used before transplantation, number of postremission chemotherapy courses before transplantation, time interval between diagnosis and transplantion, time interval between last remission and transplant, pretransplant history of bacterial or fungal infections and organisms isolated, year of transplantation as a continuous covariate, recipient age at transplantation, recipient gender, recipient CMV serology, disease stage at transplantation, donor gender, donor-recipient sex match, number of nucleated cells infused, conditioning regimen, time to reach an ANC above 0.5 Â /l, grade II-IV acute GvHD, chronic GvHD, LSBI, and CMV reactivation before and after day 100, duration and maximum dose of corticosteroids used. Post-transplantation events occurring after day 100, that is, LSBI, viral infections, corticosteroid therapy, and chronic GvHD were analysed as time-dependent covariates. Covariates found significant at a P-value below 0.10 Allogenic bone marrow transplantation for AML M Robin et al were subsequently introduced in proportional hazards Cox models, and selected via a stepwise procedure. Departure from the proportional hazard assumption was assessed using a graphical approach and partial residuals. Timedependent or stratified Cox models were used when covariates did not meet the proportional hazard assumption. Potential interactions between the significant covariates were tested adding cross-product terms to the final models. When groups were compared according to continuous covariates, the Man-Whitney U test or Kruskal-Wallis one-way ANOVA on ranks test were used for difference in medians. According to the group sizes, w 2 or Fisher's exact tests were used to compare categorical covariates. S-PLUS 2000 Professional was used for all statistical analysis.
Results
EFS and relapse incidence
The 7-year EFS and relapse incidence for the 97 patients surviving beyond day 100 post transplantation were 57% (95% CI: 47-70%), and 27% (95% CI: 15-37%), respectively (see Figure 1a ). Main causes of death were chronic GvHD (n ¼ 13, of which seven patients had a concurrent infection), relapses (n ¼ 13), infections without chronic GvHD (n ¼ 3), and secondary solid cancers (glioblastoma n ¼ 1, sinus carcinoma n ¼ 1 (Figure 1c, 1d) . Finally, an extended Cox model including post-transplant covariates was fitted with the overall group of patients (Table 3) .
Transplant-related mortality
The 7-year TRM rate was 22% for the overall group (95% CI: 11-32%). It was 23% for patients grafted in CR1 (95% CI: 10-33%), and 18% for those in CR2 (95% CI: 0-35%).
On multivariate analysis, a first Cox model stratified on recipient age (o20 years vs X20 years) excluding posttransplant covariates was fitted. In that model, multiple courses on 7-year EFS in patients transplanted in first remission. A total of 56 patients received less than three courses of postremission chemotherapy and 20 more than three courses; their 7-year leukaemia-free survival rates were 70% (95% CI: 58-85%) vs 27% (95% CI: 11-77%), respectively, P ¼ 0.005. Among the 20 patients receiving more than three postremission CTs, 11 died; causes of death included: GvHD (n ¼ 6), relapse (n ¼ 4), and late marrow failure (n ¼ 1); no difference was noted between the cause of death of these 11 patients and those of the 15 patients receiving less than three postremission CTs (data not shown). (c) Influence of conditioning regimen on 7-year EFS. In all, 17 patients received an intensified regimen and 80 received a standard regimen which led to an estimated KM rate for 7-years EFS of 39% (95% CI: 21-73%) vs 79% (95% CI: 50-75) respectively, P ¼ 0.005. (d) Influence of pretransplant Gramnegative bacteriaemia on 7-year EFS. Among nine patients who developed one or more episodes of Gram-negative bacteriaemia before SCT, the 7-year EFS was 18% (95% CI: 3-100%) whereas for patients who did not develop pretransplant infection, the 7-years EFS was 63% (95% CI: 52-76%), P ¼ 0. Table 3 .
Chronic GvHD
In total, 35 patients developed chronic GvHD which was extensive in 27 cases. The 7-year incidence of overall and extensive chronic GvHD was 40% (95% CI: 29-50%) and 32% (95% CI: 21-41%), respectively. Progressive forms of chronic GvHD occurred in 12 cases while de novo chronic GvHD was observed in 23 patients. On a first multivariate Cox model stratified on recipient age, a major ABO blood group incompatibility (RR: 2.46, 95% CI: 1.11-5.43, P ¼ 0.026) and intensified conditioning regimens (RR: 2.13, 95% CI: 0.99-4.60, P ¼ 0.054) were significant predictors for chronic GvHD. Results of the Cox models for chronic GvHD, and extensive chronic GvHD, stratified on age and including post-transplant covariates are summarised in Table 3. In the first CR patients, the number of postremission CT courses before transplantation (RR: 3.49, 95% CI: 1.47-8.27, P ¼ 0.004), major ABO blood group incompatibility (RR: 3.00, 95% CI: 1.27-7.09, P ¼ 0.012), platelet count above 20 Â 10 9 /l not reached by day À100 (RR: 2.54, 95% CI: 1.01-6.37, P ¼ 0.047), and grade II-IV acute GvHD (RR: 2.26, 95% CI: .96-5.35, P ¼ 0.06) were significantly associated with chronic GvHD.
Late infections
Bacterial infections: In all, 24 patients developed one or more (n ¼ 5) late severe bacterial infections (Table 4) , which occurred at a median of 7.5 months post transplantation (range: 4 months -5 years). The 7-year probability of LSBI was 35% (95% CI: 26-46%) (Figure 3a ). All cases of acute pyelonephritis were caused by E. coli; whereas, in most cases of pneumonia (83%), no bacterial documentation was obtained since antibiotics were started early after the onset of symptoms. Most of the bacteriaemias/septicaemias were observed during the first 6 months post transplantation (78%), whereas most pneumonias (83%) and all unusual infections (osteitis, meningitis, empyema) were observed after the first 6 months post transplant. Previous bacterial infection during the first 100 days post transplantation was not associated with an higher risk of LSBI. On multivariate analysis including pretransplant covariates, a previous history of Gram-negative bacteriaemia before transplantation (RR: 2.85, 95% CI: 0.94-8.60, P ¼ 0.063), and TBI (RR: 3.85, 95% CI: 1.50-9.86, P ¼ 0.005) were associated with a higher risk of LSBI, as confirmed in Figure 3b and 3c. In the final model in which post-transplant covariates were added, extensive GvHD also appeared also as a major risk factor (see Table 3 , Figure 3d ).
Other infections. Late CMV reactivation occurred in nine cases (isolated blood antigenaemia n ¼ 6, gastroenteritis n ¼ 2, pneumoniae n ¼ 1), leading to a 7-year probability of CMV reactivation of 10% (95% CI: 6-16%). CMVreactivation occurred at a median of 5 months posttransplantation, without any reactivation after 1 year. Twothirds of these patients had already experienced CMV reactivation before day 100. In all, 24 patients developed nonlethal varicella zoster virus (VZV) infections, leading to a 7-year probability of VZV infection of 32% (95% CI: 20-43%). These VZV infections occurred at a median of 12 months from transplantation (range: 5 months -3.8 years). Other viral infections were post-transfusion viral hepatitis C (n ¼ 7), parvovirus B19-related erythroblastopenia (n ¼ 2), Epstein-Barr virus related lymphoproliferative disorder (n ¼ 1), and human immunodeficiency virus (n ¼ 1). With regard to fungal infections, nine patients developed invasive aspergillosis at a median of 5 months from transplantation (range: 3 -6 months), and two patients developed candidaemia. /l from 0.5 Â 10 9 /l. plt=platelet rate.
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Non infectious complications
Aseptic osteonecrosis occurred in 14 cases, at a median of 12 months from transplantation (range: 10 -84 months). The 7-year probability of developing this complication was 28%. Nine patients required surgery at a median of 8 months from diagnosis (range: 10 days -4 years). On multivariate analysis, factors associated with an increased risk of aseptic osteonecrosis were grade II-IV acute GvHD (RR: 2.91, 95% CI: 1.08-7.87, P ¼ 0.035), and a platelet count X20 Â 10 9 /l not reached by day À100 (RR: 5.00, 95% CI: 1.72-14.49, P ¼ 0.003). (95% CI: 8-61%) for patients receiving more than two postremission CTs, P ¼ 0.03. (c) Impact of major ABO incompatibility on 7-year incidence TRM. Projected incidence at 7 years for TRM was 17% (95% CI: 28%) and 42% (95% CI: 13-62%) for major ABO incompatibility and others, P ¼ 0.002. 19 patients had a major ABO incompatibility and 77 patients had a minor ABO incompatibility or a standard ABO compatibility. (d) Impact of conditioning regimen on 7-years TRM. Patients conditioned with an intensified regimen had a 7-year TRM of 45% (95% CI: 8-67%) whereas patients conditioned with a standard regimen had a 7-year TRM of 18% (95% CI: 7-28%), P ¼ 0.06.
Cataracts were diagnosed in 18 cases at a median of 3 years post transplant (range: 13 months -6 years), leading to a 7-year probability of 36%. Conditioning including single dose TBI was the only risk factor identified for this complication (Kaplan-Meier estimate: 73%, RR: 4.54, 95% CI: 1.72-12.00, P ¼ 0.002).
In all, 14 patients, had thyroid insufficiency, of whom 12 had received a conditioning regimen including TBI. Nine out of 28 patients less than 16 years of age had growth retardation; four of them required growth hormone replacement. Growth retardation was only observed in children who were between 6 and 12 years of age at the time of SCT (Kaplan-Meier estimate: 57%), six of whom had been conditioned with TBI. No growth retardation was observed among children aged from 1 to 5 years at the time of SCT including one patient conditioned with TBI. In total, 16 children were assessable for puberty. Delayed puberty with gonadal insufficiency was observed in seven patients.
Pulmonary restrictive syndromes were diagnosed in 11 patients. In addition, two patients had chronic bronchiolitis with interstitial and obstructive syndromes. Symptomatic cardiac failure requiring inotropic drugs and diuretics occurred in six patients. All these patients had received a cumulative dose of anthracycline below 300 mg/m 2 . Four patients developed second malignancies (glioblastoma, melanoma, breast cancer, and sinus cancer diagnosed 8, 4, 7, and 10 years after transplantation). These patients were 7, 12, 38, and 50 years old at SCT; all had received TBI during the conditioning regimen, but none had developed chronic GvHD. The woman who developed breast cancer also had severe dysplastic lesions of the cervix 6 months after SCT.
General health status and return to work or school
Among 71 patients surviving more than a year following SCT, 75% had a good functional status (0-1 WHO scale). In total, 61% percent of the patients returned to work or school (children 90 vs 42% from adults, Po0.001). Of note, neuropsychological changes including overt depression requiring treatment were diagnosed in 14 patients.
Discussion
We studied long-term morbidity and mortality in 97 consecutive recipients with AML in CR1 or CR2 with particular attention to pretransplant and post-transplant factors that could influence late morbidity. Among pretransplant parameters, prognostic factors such as age, hyperleukocytosis, disease status and cytogenetics at diagnosis [29] [30] [31] [32] [33] had no significant impact on outcome in our series, as reported by others. 34, 35 The outcome of paediatric patients was not significantly better than that of adults although if they were less likely to develop GvHD. Similarly, no significant difference was observed between patients grafted in CR1, as compared to those grafted in CR2 for EFS, TRM, GvHD or late morbidity. However, the limited number of patients obviously precludes any definitive conclusions. Cytogenetics were assessable in only two thirds of patients. According to ongoing protocols, patients with favorable cytogenetics were first treated with chemotherapy only and were transplanted in CR2 if they relapsed. This therapeutic option thus leads to a statistical bias and can explain why cytogenetics data do not influence outcome in our study. Other known cytogenetic classifications were no more relevant in our statistical models (data not shown) in showing any impact on outcome. Finally, when we analysed only patients in CR1, we failed to find any impact of cytogenetics on outcome but the small number of available karyotypes reduced the statistical power (data not shown).
In our analysis, it appeared that the number of CT courses had a detrimental effect on both EFS and TRM. Intensive postremission therapy with intermediate or HiDAC has been proven to be better than conventional chemotherapy especially in young patients 36 leading to an increased use of HiDAC. In two studies, the impact of HiDAC before transplant failed to result in any difference in patient outcome. 37, 38 In our study, long-term outcome of patients treated with HiDAC (mostly adults in CR2) was identical to that of those who did not receive HiDAC. In contrast, multiple chemotherapy courses seemed deleterious in our patients, as already suggested by others. 39, 40 However, there was a clear relation between the number of postremission CTs in CR1 patients and the interval between remission and SCT. Other authors have already described the favourable influence of early SCT on outcome of patients with AML. 41 Chemotherapy-induced damage of epithelial cells triggering GvHD 42, 43 could be implicated in the deleterious impact of pretransplant chemotherapy courses.
We analysed the pretransplant bacterial history and, in particular, gram-negative bacteriaemias which were most frequently nosocomial infections. Gram-negative bacteriaemia did not correlate with the number of postremission chemotherapy courses or pretransplant HiDAC, and was an independent risk factor for LSBI and EFS. These infections occurred mainly in patients in CR1 (88%).
Total body irradiation was associated with the development of late complications including cataracts, avascular necrosis of bone, endocrine deficiencies and cancers as reported by others. [44] [45] [46] [47] Furthermore, in our series TBI was an independent risk factor for LSBI (RR: 3.45), confirming the results of a recent report. 48 An intensified conditioning regimen which consisted of the combination of a standard conditioning regimen with another drug was used in 17 patients, of whom 11 were grafted in CR2. On multivariate analysis, intensified regimens had an impact on GvHD, TRM and EFS. Similarly, previous reports noted high rates of regimen-related toxicity in adult patients with advanced disease who received intensified conditioning. 49, 50 A randomised trial comparing the effectiveness of 12 with 15.75 Gy in patients with AML in CR1 concluded that the higher TBI dose resulted in a decreased relapse rate but in an increase in TRM, and therefore, had no positive impact on EFS. 51 Major ABO incompatibility appeared as a risk factor for chronic GvHD and TRM on multivariate analysis. There is a relation between ABO incompatibility and the number of nucleated cells transplanted (poorer) as observed by others. 52, 53 Thus, necessary ex vivo manipulation of the graft impaired engraftment by decreasing the number of nucleated cells and by altering the composition of the graft.
Time to reach platelets 420 Â 10 9 /l was a risk factor for chronic GvHD independent of acute GvHD indicating that delayed platelet reconstitution is predictive for subsequent chronic GvHD. Kinetics of engraftment measured by the time between 0.5 Â 10 9 /l and above 1.0 Â 10 9 /l ANC was an independent risk factor for EFS on multivariate analysis, including post-transplant and time-dependant covariates.
Late complications were dominated by chronic GvHD and LSBI which occurred, respectively, in 40 and 36% of the patients. Both remained major risk factors for TRM. On multivariate analysis, risk factors for chronic GvHD were all related to pretransplant or early post-transplant factors, that is, number of postremission CTs, intensified regimens, major ABO incompatibility, engraftment and acute GvHD. Extensive chronic GvHD, a major risk factor for late infections, 48, 54 was a risk factor for LSBI on multivariate analysis, whereas limited GvHD was not. Steroid treatment is also a well-known risk factor for other infections such as invasive aspergillosis [55] [56] [57] and for other complications including diabetes, growth hormone deficiency or cataract. [58] [59] [60] [61] Aspergillosis and CMV occurred in about 10% of the patients, thus precluding any meaningful analysis of risk factors. Delayed CMV infections were not explained by ganciclovir prophylaxis in our series in contrast to Nguyen, 62 but most patients received high-dose intravenous acyclovir until engraftment which is reported to decrease CMV infection rate. 63, 64 Late onset of VZV infections were frequent but rarely disseminated as already reported 65 and we observed low rates of VZV-related mortality in contrast to older series [66] [67] [68] [69] most probably linked to the success of systematic prophylaxis with acyclovir. 65, 70 Thyroid hormone insufficiency occurred in 14 patients. One-third of assessable children had delayed growth, half of whom had low growth hormone levels. This mainly concerned children between 6 and 12 years of age. Michel et al 58 have already reported a greater height loss in patients transplanted within puberty. The incidence of growth retardation reported here is in keeping with that reported in the literature where TBI was the major risk factor. 44, 61, 71 Cardiac failure occurred in six patients including one very late case, 8 years after SCT. Although rarely reported after SCT this complication is increasingly described in long-term survivors of childhood cancers including leukaemia. 58, 72, 73 Thus, the cumulative effects of pretransplant chemotherapy with post-transplant complications such as the X-syndrome 74 may increase the risk of late vascular complications which should be amenable to early detection and even prevention. Four patients, all of whom had received irradiation with the conditioning regimen, developed solid tumours and two of them died from their tumour 4 and 10 years post-transplant. Since cancer incidence increases over time, high-risk situations must be recognised especially in children who are prone to second cancers. 45, 75 In conclusion, this retrospective analysis strongly suggests that pregraft factors such as chemotherapy, bacterial infections, conditioning regimen and graft characteristics have a major impact on late morbidity and mortality.
